http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011118227-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011118227-A |
| titleOfInvention | CANCER TREATMENT METHOD |
| abstract | 1. A method of treating cancer in a patient in need of treatment, comprising sequentially or co-administering a compound of formula I or a pharmaceutically acceptable salt thereof and another therapeutic agent:! ! or its tautomer, or a pharmaceutically acceptable salt thereof, where! R2 is C1-3 alkyl or cyclopropyl; ! R9 is halogen, C1-3-alkyl, -O- (C1-3-alkyl), -S- (C1-3-alkyl) or CF3 and! p is 1-2. ! 2. The method according to claim 1, where the specified therapeutic agent is selected from taxanes, bcr-abl inhibitors, EGFR inhibitors, DNA damaging agents and antimetabolites. ! 3. The method according to claim 1 or 2, where the specified therapeutic agent is selected from paclitaxel, glivec, dasatinib, nilotinib, tarseva, iressa, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC and 5-FU. ! 4. The method according to claim 1 or 2, wherein said therapeutic agent is selected from camptothecin, doxorubicin, idarubicin, cisplatin, taxol, taxotere, vincristine, tarseva, MEK inhibitor, U0126, KSP inhibitor, vorinostat, glivec, dasatinib and nilotinib. ! 5. A method of treating cancer in a patient in need of treatment, comprising sequentially or co-administering one or more of the following compounds or their pharmaceutically acceptable salts and another therapeutic agent:! ! 6. The method according to claim 5, where the specified therapeutic agent is selected from taxanes, bcr-abl inhibitors, EGFR inhibitors, DNA damaging agents and antimetabolites. ! 7. The method according to claim 5 or 6, where the specified therapeutic agent is selected from paclitaxel, glivec, dasatinib, nilotinib, tarseva, iressa, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC and 5-FU. ! 8. The method according to claim 5 or 6, where the specified therapeutic agent |
| priorityDate | 2005-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.